NCT04645160 2026-03-11
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
Clinical Trials
8 trialsNCT05000294 2026-02-18
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
University of Florida
Phase 1/2 Suspended
NCT01835223 2020-10-28
Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery
Roswell Park Cancer Institute
Phase 1/2 Completed
NCT01058655 2017-04-13
RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT01807156 2016-04-22
Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer
Emory University
Phase 2 Terminated
NCT01478594 2015-07-08
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
AVEO Pharmaceuticals, Inc.
Phase 2 Completed
NCT01306630 2014-01-27
A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
AVEO Pharmaceuticals, Inc.
Phase 1 Completed
NCT00660153 2012-08-28
Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers
AVEO Pharmaceuticals, Inc.
Phase 1 Completed